Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Multi-Center, Placebo-Controlled, Double-Blinded, Randomized, Dose Ranging Study of the Preliminary Efficacy of DARE-HPV to Treat Persistent High-Risk Human Papillomavirus (HPV) Genital Infection

NCT07601074 is registered in ClinicalTrials.gov with Daré Bioscience, Inc. as lead sponsor.

NCT NCT07601074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07601074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Multi-Center, Placebo-Controlled, Double-Blinded, Randomized, Dose Ranging Study of the Preliminary Efficacy of DARE-HPV to Treat Persistent High-Risk Human Papillomavirus (HPV) Genital Infection
Lead sponsor
Daré Bioscience, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
July 17, 2026
Completion date
December 31, 2027
Enrollment
118 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk human papillomavirus infection, human papilloma virus (hpv)